Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosisMinoru Nakamura, Hiromi Ishibashi, Yasushi Takii et al.|Hepatology|2006Cited by 365
AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCCKentaroh Yamamoto, Norihiro Kokudo, Hiroshi Imamura et al.|Journal of Gastroenterology|2010Cited by 192
Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitisTamás Tornai, Mária Papp, Eszter Pályu et al.|World Journal of Gastroenterology|2017Cited by 48